Galectin-3-binding protein: A serological and histological assessment in accordance with hepatitis C-related liver fibrosis

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 9, 2010, Pages 1066-1073

  Cheung, Kin Jip ^a   Libbrecht, Louis ^a   Tilleman, Kelly ^b   Deforce, Dieter ^b   Colle, Isabelle ^a   Van Vlierberghe, Hans ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

alcohol; biomarker; ELISA; galectin 3 binding protein; HCV; immunohistochemistry; liver biopsy; liver cirrhosis; liver fibrosis; serum; western blot

Indexed keywords

BINDING PROTEIN; GALECTIN 3; PROTEOME;

ADULT; ALCOHOL LIVER CIRRHOSIS; ANTIBODY AFFINITY; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HEPATITIS C; HEPATITIS C VIRUS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; SEROLOGY; WESTERN BLOTTING;

ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY; CARRIER PROTEINS; GLYCOPROTEINS; GLYCOSYLATION; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, ALCOHOLIC; MIDDLE AGED;

EID: 77955439381     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328337d602     Document Type: Article

References (59)

1. Burroughs A, Mcnamara D. Liver disease in Europe. Aliment Pharmacol Ther 2003; 18 (Suppl 3):54-59.
2. Pellicano R, Mladenova I, Dimitrova SM, Bruno CM, Sciacca C, Rizzetto M. The epidemiology of hepatitis C virus infection. An update for clinicians. Minerva Gastroenterol Dietol 2004; 50:1-7.
3. Seeff L B. Natural history of hepatitis C. Hepatology 1997; 26:21S-28S.
4. Tsukada S, Parsons C J, Rippe R A. Mechanisms of liver fibrosis. Clin Chim Acta 2006; 364:33-60.
5. De Francesco R, Tomei L, Altamura S, Summa V, Migliaccio G. Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res 2003; 58:1-16.
6. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343:1666-1672.
7. Poynard T, Yuen M F, Ratziu V, Lai C L. Viral hepatitis C. Lancet 2003; 362:2095-2100.
8. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38:1449-1457.
9. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344:495-500.
10. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97:2614-2618.
11. Standish RA, Cholongitas E, Dhillon A, Burroughs AK, Dhillon AP. An appraisal of the histopathological assessment of liver fibrosis. Gut 2006; 55:569-578.
12. Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat 2009; 16:418-429.
13. Hellstern S, Sasaki T, Fauser C, Lustig A, Timpl R, Engel J. Functional studies on recombinant domains of Mac-2-binding protein. J Biol Chem 2002; 277:15690-15696.
14. Almasio PL, Di Marco V, Bonura C, Fuschi P, Camma C, Lo Iacono O, et al. Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon. Dig Dis Sci 1999; 44:1013-1019.
15. Artini M, Natoli C, Tinari N, Costanzo A, Marinelli R, Balsano C, et al. Elevated serum levels of 90K/MAC-2 BP predict unresponsiveness to alpha-interferon therapy in chronic HCV hepatitis patients. J Hepatol 1996; 25:212-217.
16. Iacobelli S, Arno E, D'orazio A, Coletti G. Detection of antigens recognized by a novel monoclonal antibody in tissue and serum from patients with breast cancer. Cancer Res 1986; 46:3005-3010.
17. Iacovazzi PA, Cozzolongo R, Lanzillotta E, Frisullo S, Guerra V, Correale M. Serum 90K/Mac-2 binding protein (Mac-2BP) as a response predictor to peginterferon and ribavirin combined treatment in HCV chronic patients. Immunopharmacol Immunotoxicol 2008; 30:687-700.
18. Iacovazzi PA, Trisolini A, Barletta D, Elba S, Manghisi OG, Correale M. Serum 90K/MAC-2BP glycoprotein in patients with liver cirrhosis and hepatocellular carcinoma: a comparison with alpha-fetoprotein. Clin Chem Lab Med 2001; 39:961-965.
19. Jallal B, Powell J, Zachwieja J, Brakebusch C, Germain L, Jacobs J, et al. Suppression of tumor growth in vivo by local and systemic 90 K level increase. Cancer Res 1995; 55:3223-3227.
20. Kittl EM, Hofmann J, Hartmann G, Sebesta C, Beer F, Bauer K, et al. Serum protein 90K/Mac-2BP is an independent predictor of disease severity during hepatitis C virus infection. Clin Chem Lab Med 2000; 38:205-208.
21. Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schulick R, et al. Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 2004; 101:1609-1615.
22. Marchetti A, Tinari N, Buttitta F, Chella A, Angeletti CA, Sacco R, et al. Expression of 90 K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. Cancer Res 2002; 62:2535-2539.
23. Ozaki Y, Kontani K, Hanaoka J, Chano T, Teramoto K, Tezuka N, et al. Expression and immunogenicity of a tumor-associated antigen, 90K/Mac-2 binding protein, in lung carcinoma. Cancer 2002; 95:1954-1962.
24. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencerbased total serum protein glycomics. Nat Med 2004; 10:429-434.
25. Gravel P, Walzer C, Aubry C, Balant LP, Yersin B, Hochstrasser DF, et al. New alterations of serum glycoproteins in alcoholic and cirrhotic patients revealed by high resolution two-dimensional gel electrophoresis. Biochem Biophys Res Commun 1996; 220:78-85.
26. Cyster JG, Shotton DM, Williams AF. The dimensions of the T lymphocyte glycoprotein leukosialin and identification of linear protein epitopes that can be modified by glycosylation. Embo J 1991; 10:893-902.
27. Davis D, Stephens DM,Willers C, Lachmann PJ. Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. J Gen Virol 1990; 71:2889-2898.
28. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20:15-20.
29. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24:289-293.
30. Pinzani M. Liver fibrosis. Springer Semin Immunopathol 1999; 21:475-490.
31. Fukaya Y, Shimada H, Wang LC, Zandi E, Declerck YA. Identification of galectin-3-binding protein as a factor secreted by tumor cells that stimulates interleukin-6 expression in the bone marrow stroma. J Biol Chem 2008; 283:18573-18581.
32. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128:343-350.
33. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006; 55:403-408.
34. Cheung KJ, Tilleman K, Deforce D, Colle I, Van Vlierberghe H. Proteomics in liver fibrosis is more than meets the eye. Eur J Gastroenterol Hepatol 2008; 20:450-464.
35. Vanderschaeghe D, Laroy W, Sablon E, Halfon P, Van Hecke A, Delanghe J, et al. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteomics 2009; 8:986-994.
36. Denzer UW, Luth S. Non-invasive diagnosis and monitoring of liver fibrosis and cirrhosis. Best Pract Res Clin Gastroenterol 2009; 23:453-460.
37. Afdhal NH, Nunes D. Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004; 99:1160-1174.
38. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008; 134:1670-1681.
39. Castera L, Hezode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Pawlotsky JM, et al.Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut 2003; 52:288-292.
40. Fartoux L, Chazouilleres O, Wendum D, Poupon R, Serfaty L. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology 2005; 41:82-87.
41. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29:1215-1219.
42. Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Komatsu N, et al. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. J Hepatol 2008; 48:736-742.
43. Patel K, Zekry A, Mchutchison JG. Steatosis and chronic hepatitis C virus infection: mechanisms and significance. Clin Liver Dis 2005; 9:399-410. vi.
44. Patton HM, Patel K, Behling C, Bylund D, Blatt LM, Vallee M, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004; 40:484-490.
45. Nguyen T, Tang W, Nan L, Deleon M, French SW. The role of bile duct reactive change in the pathogenesis of liver fibrosis due to hepatitis C. Exp Mol Pathol 2005; 79:95-99.
46. Roskams TA, Theise ND, Balabaud C, Bhagat G, Bhathal PS, Bioulac-Sage P, et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 2004; 39:1739-1745.
47. Kristiansen TZ, Bunkenborg J, Gronborg M, Molina H, Thuluvath PJ, Argani P, et al. A proteomic analysis of human bile. Mol Cell Proteomics 2004; 3:715-728.
48. Alter H. Viral hepatitis. Hepatology 2006; 43:S230-S234.
49. Mcclain CJ, Song Z, Barve SS, Hill DB, Deaciuc I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004; 287:G497-G502.
50. Tanikawa K. Pathogenesis and treatment of hepatitis C virus-related liver diseases. Hepatobiliary Pancreat Dis Int 2004; 3:17-20.
51. Tsukamoto H, Lu SC. Current concepts in the pathogenesis of alcoholic liver injury. Faseb J 2001; 15:1335-1349.
52. Pawlotsky JM. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol 2004; 12:96-102.
53. Bigger CB, Guerra B, Brasky KM, Hubbard G, Beard MR, Luxon BA, et al. Intrahepatic gene expression during chronic hepatitis C virus infection in chimpanzees. J Virol 2004; 78:13779-13792.
54. Natoli C, Iacobelli S, Kohn L. The immune stimulatory protein 90 K increases major histocompatibility complex class I expression in a human breast cancer cell line. Biochem Biophys Res Commun 1996; 225:617-620.
55. Ullrich A, Sures I, D'egidio M, Jallal B, Powell TJ, Herbst R, et al. The secreted tumor-associated antigen 90 K is a potent immune stimulator. J Biol Chem 1994; 269:18401-18407.
56. Henderson NC, Mackinnon AC, Farnworth SL, Kipari T, Haslett C, Iredale JP, et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am J Pathol 2008; 172:288-298.
57. Henderson NC, Mackinnon AC, Farnworth SL, Poirier F, Russo FP, Iredale JP, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis. Proc Natl Acad Sci U S A 2006; 103:5060-5065.
58. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001; 357:1069-1075.
59. Adams LA, Bulsara M, Rossi E, Deboer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51:1867-1873.